Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs
- PMID: 25663663
- PMCID: PMC4413050
- DOI: 10.1002/pbc.25435
Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs
Abstract
Background: Antibiotic delivery to patients with fever and neutropenia (F&N) in <60 min is an increasingly important quality measure for oncology centers, but several published reports indicate that a time to antibiotic delivery (TTA) of <60 min is quite difficult to achieve. Here we report a quality improvement (QI) effort that sought to decrease TTA and assess associated clinical outcomes in pediatric patients with cancer and F&N.
Procedure: We used Lean-Methodology and a Plan-Do-Study-Act approach to direct QI efforts and prospectively tracked TTA measures and associated clinical outcomes (length of stay, duration of fever, use of imaging studies to search for occult infection, bacteremia, intensive care unit (ICU) consultation or admission, and mortality). We then performed statistical analysis to determine the impact of our QI interventions on total TTA, sub-process times, and clinical outcomes.
Results: Our QI interventions significantly improved TTA such that we are now able to deliver antibiotics in <60 min nearly 100% of the time. All TTA sub-process times also improved. Moreover, achieving TTA <60 min significantly reduced the need for ICU consultation or admission (P = 0.003) in this population.
Conclusion: Here we describe our QI effort along with a detailed assessment of several associated clinical outcomes. These data indicate that decreasing TTA to <60 min is achievable and associated with improved outcomes in pediatric patients with cancer and F&N.
Keywords: antibiotics time; fever; neutropenia; quality improvement.
© 2015 The Authors. Pediatric Blood & Cancer Published by Wiley Periodicals, Inc.
Figures
References
-
- Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four eortc studies. International antimicrobial therapy cooperative group (iatcg) of the european organization for research and treatment of cancer (eortc) Br J Haematol. 1997;99:580–588. - PubMed
-
- Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39:S32–S37. - PubMed
-
- Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. New Eng J Med. 1993;328:1323–1332. - PubMed
-
- Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–2266. - PubMed
-
- Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
